Advances in the Biology and Treatment of Bone Disease in Multiple Myeloma
- 15 March 2011
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 17 (6), 1278-1286
- https://doi.org/10.1158/1078-0432.ccr-10-1804
Abstract
Osteolytic bone disease is pathognomonic of multiple myeloma (MM) and affects more than 80% of patients. Bone disease results in skeletal-related events (SRE) such as vertebral compression fractures, which may cause cord compression, hypercalcemia, pathologic fractures that require radiation or surgical fixation, and severe pain. All of these not only result in a negative impact on quality of life but also adversely impact overall survival. Osteolytic disease is a consequence of increased osteoclast (OC) activation along with osteoblast (OB) inhibition, resulting in altered bone remodeling. OC number and activity are increased in MM via cytokine deregulation within the bone marrow (BM) milieu, whereas negative regulators of OB differentiation suppress bone formation. Bisphosphonates are a well-established treatment of myeloma-related skeletal disease and are the current standard of care. However, complications arising from their long-term use have prompted studies of schedule optimization and alternate strategies. Several novel agents are currently under investigation for their positive effect on bone remodeling via OC inhibition. The identification of negative regulators of OB differentiation has prompted the use of anabolic agents. In addition to restoring bone remodeling, these drugs may inhibit tumor growth in vivo. Future studies will look to combine or sequence all of these agents with the goal of not only alleviating morbidity from bone disease but also capitalizing on the resultant antitumor activity. Clin Cancer Res; 17(6); 1278–86. ©2011 AACR.Keywords
This publication has 87 references indexed in Scilit:
- Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone diseaseProceedings of the National Academy of Sciences, 2010
- Increased signaling through p62 in the marrow microenvironment increases myeloma cell growth and osteoclast formationBlood, 2009
- Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast CancerNew England Journal of Medicine, 2009
- Giant Osteoclast Formation and Long-Term Oral Bisphosphonate TherapyNew England Journal of Medicine, 2009
- A soluble activin Type IIA receptor induces bone formation and improves skeletal integrityProceedings of the National Academy of Sciences, 2008
- Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivoBlood, 2008
- Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in miceJCI Insight, 2008
- MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclastsBlood, 2007
- Fibroblasts in cancerNature Reviews Cancer, 2006
- Mechanisms of Bone MetastasisNew England Journal of Medicine, 2004